Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:FOXP4-PGC

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: FOXP4-PGC
	FusionPDB ID: 31242
	FusionGDB2.0 ID: 31242
		Hgene	Tgene
	Gene symbol	FOXP4	PGC
	Gene ID	116113	5225
	Gene name	forkhead box P4	progastricsin
	Synonyms	hFKHLA	PEPC\|PGII
	Cytomap	6p21.1	6p21.1
	Type of gene	protein-coding	protein-coding
	Description	forkhead box protein P4fork head-related protein like Awinged-helix repressor FOXP4	gastricsinpepsin Cpepsinogen Cpepsinogen group IIpreprogastricsin
	Modification date	20200313	20200313
	UniProtAcc	Q8IVH2 Main function of 5'-partner protein: FUNCTION: Transcriptional repressor that represses lung-specific expression. {ECO:0000250}.	PERM1 Main function of 5'-partner protein: 790
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000307972, ENST00000373057, ENST00000373060, ENST00000373063, ENST00000409208,	ENST00000373025, ENST00000425343,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	7 X 7 X 4=196	24 X 21 X 8=4032
	# samples	10	25
	** MAII score	log2(10/196*10)=-0.970853654340483 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(25/4032*10)=-4.01149563883783 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: FOXP4 [Title/Abstract] AND PGC [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: FOXP4 [Title/Abstract] AND PGC [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	FOXP4(41545819)-PGC(41710227), # samples:1
Anticipated loss of major functional domain due to fusion event.	FOXP4-PGC seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. FOXP4-PGC seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner

Gene

GO ID

GO term

PubMed ID

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr6:41545819/chr6:41710227)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across FOXP4 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across PGC (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000373060	FOXP4	chr6	41545819	+	ENST00000373025	PGC	chr6	41710227	-	1619	758	458	1477	339
ENST00000373060	FOXP4	chr6	41545819	+	ENST00000425343	PGC	chr6	41710227	-	1396	758	458	1258	266
ENST00000373063	FOXP4	chr6	41545819	+	ENST00000373025	PGC	chr6	41710227	-	1619	758	458	1477	339
ENST00000373063	FOXP4	chr6	41545819	+	ENST00000425343	PGC	chr6	41710227	-	1396	758	458	1258	266
ENST00000409208	FOXP4	chr6	41545819	+	ENST00000373025	PGC	chr6	41710227	-	1472	611	311	1330	339
ENST00000409208	FOXP4	chr6	41545819	+	ENST00000425343	PGC	chr6	41710227	-	1249	611	311	1111	266
ENST00000373057	FOXP4	chr6	41545819	+	ENST00000373025	PGC	chr6	41710227	-	1397	536	236	1255	339
ENST00000373057	FOXP4	chr6	41545819	+	ENST00000425343	PGC	chr6	41710227	-	1174	536	236	1036	266
ENST00000307972	FOXP4	chr6	41545819	+	ENST00000373025	PGC	chr6	41710227	-	1173	312	12	1031	339
ENST00000307972	FOXP4	chr6	41545819	+	ENST00000425343	PGC	chr6	41710227	-	950	312	12	812	266

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000373060	ENST00000373025	FOXP4	chr6	41545819	+	PGC	chr6	41710227	-	0.004401829	0.99559826
ENST00000373060	ENST00000425343	FOXP4	chr6	41545819	+	PGC	chr6	41710227	-	0.032445118	0.96755487
ENST00000373063	ENST00000373025	FOXP4	chr6	41545819	+	PGC	chr6	41710227	-	0.004401829	0.99559826
ENST00000373063	ENST00000425343	FOXP4	chr6	41545819	+	PGC	chr6	41710227	-	0.032445118	0.96755487
ENST00000409208	ENST00000373025	FOXP4	chr6	41545819	+	PGC	chr6	41710227	-	0.005612061	0.9943879
ENST00000409208	ENST00000425343	FOXP4	chr6	41545819	+	PGC	chr6	41710227	-	0.038946148	0.9610539
ENST00000373057	ENST00000373025	FOXP4	chr6	41545819	+	PGC	chr6	41710227	-	0.004660257	0.99533975
ENST00000373057	ENST00000425343	FOXP4	chr6	41545819	+	PGC	chr6	41710227	-	0.038393244	0.96160674
ENST00000307972	ENST00000373025	FOXP4	chr6	41545819	+	PGC	chr6	41710227	-	0.004280862	0.99571913
ENST00000307972	ENST00000425343	FOXP4	chr6	41545819	+	PGC	chr6	41710227	-	0.054903023	0.94509697

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for FOXP4-PGC

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
FOXP4	chr6	41545819	PGC	chr6	41710227	312	100	GNNDSKQSASAVQVQSIQVPNQEFGL
FOXP4	chr6	41545819	PGC	chr6	41710227	536	100	GNNDSKQSASAVQVQSIQVPNQEFGL
FOXP4	chr6	41545819	PGC	chr6	41710227	611	100	GNNDSKQSASAVQVQSIQVPNQEFGL
FOXP4	chr6	41545819	PGC	chr6	41710227	758	100	GNNDSKQSASAVQVQSIQVPNQEFGL

Top

Potential FusionNeoAntigen Information of FOXP4-PGC in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

FOXP4-PGC_41545819_41710227.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B52:01	SAVQVQSI	0.9992	0.9796	9	17
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B13:02	VQVQSIQV	0.9576	0.7905	11	19
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B52:01	VQVQSIQV	0.9146	0.9536	11	19
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B15:16	ASAVQVQSI	0.9943	0.7862	8	17
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-A02:21	KQSASAVQV	0.986	0.6637	5	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-A02:60	KQSASAVQV	0.9827	0.5028	5	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B48:01	KQSASAVQV	0.9735	0.7876	5	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B52:01	ASAVQVQSI	0.9562	0.9778	8	17
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B13:02	KQSASAVQV	0.8839	0.923	5	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-A02:20	KQSASAVQV	0.8015	0.5358	5	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B13:01	KQSASAVQV	0.6961	0.9862	5	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B13:02	AVQVQSIQV	0.5604	0.831	10	19
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B39:13	KQSASAVQV	0.5217	0.9173	5	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B52:01	KQSASAVQV	0.0299	0.9552	5	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B13:02	SKQSASAVQV	0.5093	0.9233	4	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B51:07	SAVQVQSI	0.9991	0.9028	9	17
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-C15:06	ASAVQVQSI	0.9995	0.8583	8	17
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-C12:04	ASAVQVQSI	0.9887	0.9847	8	17
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-C06:03	ASAVQVQSI	0.9882	0.9856	8	17
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-C02:06	ASAVQVQSI	0.8328	0.9387	8	17
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B15:04	KQSASAVQV	0.7854	0.9317	5	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B48:03	KQSASAVQV	0.7348	0.6181	5	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B39:08	KQSASAVQV	0.6359	0.7962	5	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-C15:02	ASAVQVQSI	0.9996	0.8002	8	17
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-C15:05	ASAVQVQSI	0.9996	0.8739	8	17
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-A02:14	KQSASAVQV	0.9862	0.5696	5	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-A02:06	KQSASAVQV	0.986	0.6637	5	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-C16:02	ASAVQVQSI	0.9749	0.9875	8	17
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B15:73	KQSASAVQV	0.8651	0.9523	5	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B15:30	KQSASAVQV	0.7417	0.9423	5	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B40:12	KQSASAVQV	0.7348	0.6181	5	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B40:49	KQSASAVQV	0.6447	0.5535	5	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B40:21	KQSASAVQV	0.5805	0.6886	5	14
FOXP4-PGC	chr6	41545819	chr6	41710227	312	HLA-B39:02	KQSASAVQV	0.529	0.9115	5	14

Top

Potential FusionNeoAntigen Information of FOXP4-PGC in HLA II

FOXP4-PGC_41545819_41710227.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0403	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0413	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0427	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0439	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0440	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0441	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0442	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0446	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0449	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0450	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0451	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0451	SAVQVQSIQVPNQEF	9	24
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0452	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0453	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0455	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0456	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0458	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0459	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0460	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0468	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0470	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0470	SAVQVQSIQVPNQEF	9	24
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0471	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0485	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB1-0488	AVQVQSIQVPNQEFG	10	25
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB4-0101	ASAVQVQSIQVPNQE	8	23
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB4-0103	ASAVQVQSIQVPNQE	8	23
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB4-0104	ASAVQVQSIQVPNQE	8	23
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB4-0106	ASAVQVQSIQVPNQE	8	23
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB4-0107	ASAVQVQSIQVPNQE	8	23
FOXP4-PGC	chr6	41545819	chr6	41710227	312	DRB4-0108	ASAVQVQSIQVPNQE	8	23

Top

Fusion breakpoint peptide structures of FOXP4-PGC

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
7575	QSASAVQVQSIQVP	FOXP4	PGC	chr6	41545819	chr6	41710227	312

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of FOXP4-PGC

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	7575	QSASAVQVQSIQVP	-6.80686	-6.92026
HLA-B14:02	3BVN	7575	QSASAVQVQSIQVP	-5.01234	-6.04764
HLA-B52:01	3W39	7575	QSASAVQVQSIQVP	-6.71251	-6.82591
HLA-B52:01	3W39	7575	QSASAVQVQSIQVP	-4.13165	-5.16695
HLA-A11:01	4UQ2	7575	QSASAVQVQSIQVP	-4.31699	-4.43039
HLA-A11:01	4UQ2	7575	QSASAVQVQSIQVP	-4.19959	-5.23489
HLA-A24:02	5HGA	7575	QSASAVQVQSIQVP	-7.74913	-7.86253
HLA-A24:02	5HGA	7575	QSASAVQVQSIQVP	-5.75888	-6.79418
HLA-B27:03	6PZ5	7575	QSASAVQVQSIQVP	10001	10000
HLA-B44:05	3DX8	7575	QSASAVQVQSIQVP	-4.89721	-5.01061
HLA-B44:05	3DX8	7575	QSASAVQVQSIQVP	-3.74482	-4.78012
HLA-A02:01	6TDR	7575	QSASAVQVQSIQVP	-5.01451	-6.04981

Top

Vaccine Design for the FusionNeoAntigens of FOXP4-PGC

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
FOXP4-PGC	chr6	41545819	chr6	41710227	10	19	AVQVQSIQV	GCTGTGCAGGTCCAGAGCATCCAGGTC
FOXP4-PGC	chr6	41545819	chr6	41710227	11	19	VQVQSIQV	GTGCAGGTCCAGAGCATCCAGGTC
FOXP4-PGC	chr6	41545819	chr6	41710227	4	14	SKQSASAVQV	AGCAAACAGTCTGCCTCTGCTGTGCAGGTC
FOXP4-PGC	chr6	41545819	chr6	41710227	5	14	KQSASAVQV	AAACAGTCTGCCTCTGCTGTGCAGGTC
FOXP4-PGC	chr6	41545819	chr6	41710227	8	17	ASAVQVQSI	GCCTCTGCTGTGCAGGTCCAGAGCATC
FOXP4-PGC	chr6	41545819	chr6	41710227	9	17	SAVQVQSI	TCTGCTGTGCAGGTCCAGAGCATC

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
FOXP4-PGC	chr6	41545819	chr6	41710227	10	25	AVQVQSIQVPNQEFG	GCTGTGCAGGTCCAGAGCATCCAGGTCCCCAACCAGGAGTTCGGC
FOXP4-PGC	chr6	41545819	chr6	41710227	8	23	ASAVQVQSIQVPNQE	GCCTCTGCTGTGCAGGTCCAGAGCATCCAGGTCCCCAACCAGGAG
FOXP4-PGC	chr6	41545819	chr6	41710227	9	24	SAVQVQSIQVPNQEF	TCTGCTGTGCAGGTCCAGAGCATCCAGGTCCCCAACCAGGAGTTC

Top

Information of the samples that have these potential fusion neoantigens of FOXP4-PGC

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
STAD	FOXP4-PGC	chr6	41545819	ENST00000307972	chr6	41710227	ENST00000373025	TCGA-IN-A6RI

Top

Potential target of CAR-T therapy development for FOXP4-PGC

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to FOXP4-PGC

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to FOXP4-PGC

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)